One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
The dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin is an attractive therapy for diabetes, as it increases insulin release and may preserve β-cell mass. However, sitagliptin also increases β-cell release of human islet amyloid polypeptide (hIAPP), the peptide component of islet amyloid, which is cosecreted with insulin. Thus, sitagliptin treatment may promote islet amyloid formation and its associated β-cell toxicity. Conversely, metformin treatment decreases islet amyloid formation by decreasing β-cell secretory demand and could therefore offset sitagliptin's potential proamyloidogenic effects. Sitagliptin treatment has also been reported to be detrimental to the exocrine pancreas. We investigated whether long-term sitagliptin treatment, alone or with metformin, increased islet amyloid deposition and β-cell toxicity and induced pancreatic ductal proliferation, pancreatitis, and/or pancreatic metaplasia/neoplasia. hIAPP transgenic and nontransgenic littermates were followed for 1 yr on no treatment, sitagliptin, metformin, or the combination. Islet amyloid deposition, β-cell mass, insulin release, and measures of exocrine pancreas pathology were determined. Relative to untreated mice, sitagliptin treatment did not increase amyloid deposition, despite increasing hIAPP release, and prevented amyloid-induced β-cell loss. Metformin treatment alone or with sitagliptin decreased islet amyloid deposition to a similar extent vs untreated mice. Ductal proliferation was not altered among treatment groups, and no evidence of pancreatitis, ductal metaplasia, or neoplasia were observed. Therefore, long-term sitagliptin treatment stimulates β-cell secretion without increasing amyloid formation and protects against amyloid-induced β-cell loss. This suggests a novel effect of sitagliptin to protect the β-cell in type 2 diabetes that appears to occur without adverse effects on the exocrine pancreas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Masters, S. L., Dunne, A., Subramanian, S. L., Hull, R. L., Tannahill, G. M., Sharp, F. A., Becker, C., Franchi, L., Yoshihara, E., Chen, Z., et al. (2010) · Nature Immunology · doi:10.1038/ni.1935 · Cited by 1,330 · cited 1×
“In fact, we and others (33, 47) have shown that hIAPP aggregation can be proinflammatory, inducing cytokine and chemokine production in macrophages and dendritic cells in vitro.”
Self-citationPancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944 · cited 1×
“Case studies in humans have reported that use of DPP-4 inhibitors is associated with acute pancreatitis in subjects with type 2 diabetes (12, 13, 15, 43).”
Goldstein, B. J., Feinglos, M. N., Lunceford, J. K., Johnson, J., Williams-Herman, D. E., & for the Sitagliptin 036 Study Group (2007) · Diabetes Care · doi:10.2337/dc07-0627 · Cited by 509
Singh, S., Chang, H.-Y., Richards, T. M., Weiner, J. P., Clark, J. M., & Segal, J. B. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.2720 · Cited by 467 · cited 1×
“Case studies in humans have reported that use of DPP-4 inhibitors is associated with acute pancreatitis in subjects with type 2 diabetes (12, 13, 15, 43).”
Butler, A. E., Campbell-Thompson, M., Gurlo, T., Dawson, D. W., Atkinson, M., & Butler, P. C. (2013) · Diabetes · doi:10.2337/db12-1686 · Cited by 457
Evidence of Cosecretion of Islet Amyloid Polypeptide and Insulin by β-Cells
Kahn, S. E., D'Alessio, D. A., Schwartz, M. W., Fujimoto, W. Y., Ensinck, J. W., Taborsky, G. J., & Porte, D. (1990) · Diabetes · doi:10.2337/diab.39.5.634 · Cited by 454
β-cell loss and β-cell apoptosis in human type 2 diabetes are related to islet amyloid deposition
Jurgens, C. A., Toukatly, M. N., Fligner, C. L., Udayasankar, J., Subramanian, S. L., Zraika, S., Aston-Mourney, K., Carr, D. B., Westermark, P., Westermark, G. T., et al. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.02.036 · Cited by 329 · cited 1×
“One contributing factor is islet amyloid, which occurs in the majority of subjects with type 2 diabetes (7, 25).”
Self-citationVerchere, C. B., D'Alessio, D. A., Palmiter, R. D., Weir, G. C., Bonner-Weir, S., Baskin, D. G., & Kahn, S. E. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3492 · Cited by 278 · cited 1×
“As we have previously observed (20, 22, 23, 45), hIAPP transgenic mice exhibited islet amyloid formation following a year of high-fat feeding, which in the present study was associated with reduced insulin release and decreased -cell mass.”
Gier, B., Matveyenko, A. V., Kirakossian, D., Dawson, D., Dry, S. M., & Butler, P. C. (2012) · Diabetes · doi:10.2337/db11-1109 · Cited by 255
Höppener, J. W. M., Oosterwijk, C., Nieuwenhuis, M. G., Posthuma, G., Thijssen, J. H. H., Vroom, T. M., Ahrén, B., & Lips, C. J. M. (1999) · Diabetologia · doi:10.1007/s001250051175 · Cited by 153
Cited by
Incretin Action in the Pancreas: Potential Promise, Possible Perils, and Pathological Pitfalls
Drucker, D. J. (2013) · Diabetes · doi:10.2337/db13-0822 · Cited by 272
“Furthermore, sitagliptin treatment was not associated with pancreatic inflammation, necrosis, metaplasia, neoplasia, or periductal fibrosis; pancreatic mass was increased in mice treated with metformin but not in mice treated with sitagliptin (65).”
BackgroundMethodGotfredsen, C. F., Mølck, A.-M., Thorup, I., Nyborg, N. C. B., Salanti, Z., Knudsen, L. B., & Larsen, M. O. (2014) · Diabetes · doi:10.2337/db13-1087 · Cited by 60
“A recent publication used a human islet amyloid polypeptide transgenic model similar to one of the earlier studies, just in mice instead of in rats, treats the animals for 1 year instead of 12 weeks, used 20–25 animals in each group instead of 8, and found no pancreas pathology associated with sitagliptin (25,41).”
MethodAn Updated Review on Cancer Risk Associated with Incretin Mimetics and Enhancers
Tseng, C.-H., Lee, K.-Y., & Tseng, F.-H. (2015) · Journal of Environmental Science and Health, Part C · doi:10.1080/10590501.2015.1003496 · Cited by 49
“The adverse effects reported by Matveyenko and associates [101] could not be confirmed by later studies by Aston-Mourney and colleagues [102] and Forest and coauthors [103].”
BackgroundResultInfluential
Metadata
- Authors
- Aston-Mourney, K., Subramanian, S. L., Zraika, S., Samarasekera, T., Meier, D. T., Goldstein, L. C., & Hull, R. L.
- Venue
- American Journal of Physiology-Endocrinology and Metabolism
- Publisher
- American Physiological Society
- Published
- 2013-08-15
- Volume
- 305
- Issue
- 4
- Pages
- E475-E484
- ISSN
- 0193-1849 (ISSN-L)
- 1522-1555
- OpenAlex
- W2163222320
- Cited by
- 37
- References
- 13
- FWCI
- 6.59
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice. https://app.cochat.ai/papers/10.1152/ajpendo.00025.2013
- The paper
- Aston-Mourney, K., Subramanian, S. L., Zraika, S., Samarasekera, T., Meier, D. T., Goldstein, L. C., & Hull, R. L. (2013). One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice. American Journal of Physiology-Endocrinology and Metabolism. https://doi.org/10.1152/ajpendo.00025.2013
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.